Matching the Device to the Patient

Pediatric Pulmonology

Volumn 37, Issue SUPPL. 26, 2004, Pages 26-29

  Tiddens, Harm A W M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVICE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; LUNG DYSPLASIA; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; PATHOPHYSIOLOGY; PATIENT SELECTION; PRESSURIZED METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW; SKILL; ARTICLE; HUMAN;

ANTIASTHMATIC AGENT; BECLOMETASONE;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; HUMANS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 2342427739     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.70038     Document Type: Review

References (21)

1. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, and Hogg JC. 1993. Small airways dimensions in asthma and chronic obstructive pulmonary disease. American Review of Respiratory Diseases 148:1220-1225.
2. Tiddens HAWM, Pare PD, Hogg JC, Hop WCJ, Lambert R, and de Jongste JC. 1995. Cartilaginous airway dimensions and airflow obstruction in human lungs. American Journal of Respiratory and Critical Care Medicine 152:260-266.
3. Tiddens HAWM, Koopman LP, Lambert RK, Elliott WM, Hop WCJ, van der Mark TW, de Boer WJ, and de Jongste JC. 2000. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. European Respiratory Journal 15:735-742.
4. Tiddens HAWM. 2001. Respiratory distress in BPD: from morphology to therapy. Italian J of Pediatrics 27(4):514-515.
5. Janssens HM, de Jongste JC, Hop WCJ, and Tiddens HAWM. 2003. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest 123:2083-2088.
6. Laube BL, Jashnani R, Dalby RN. and Zeitlin PL. 2000. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate [In Process Citation]. Chest 118(4):1069-1076.
7. Mallol J, Rattray S, Walker G, Cook D, and Robertson CF. 1996. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 21(5):276-281.
8. Le Souef PN, and Devadason SG. 2001. Deposition of medication in children's lungs using current inhaler systems. Allergic (Suppl 1):96-A145.
9. Leach CL, Davidson PJ, and Boudreau RJ. 1998. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12(6):1346-1353.
10. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, and Lannefors L. 2001. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 18(1):228-242.
11. Everard ML, Clark AR, and Milner AD. 1992. Drug delivery from holding chambers with attached facemask. Archives on Disease in Childhood 67:580-585.
12. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, and Le Souef PN. 1994. The influence of age on aerosol deposition in children with cystic fibrosis. European Respiratory Journal 7:2185-2191.
13. Cates CJ, and Rowe BH. 2001. Holding chambers versus nebulizers for beta-agonist treatment of acute asthma. Cochrane database Syst Rev 2:CD001491.
14. Esposito-Festen JE, TV, Holland WP, and Tiddens HAWM. 2002. Efficiency of aerosol delivery by pMDI-spacer to young children strongly depends on optimal seal of the facemask. Am J Resp Crit Care Med 165:A188.
15. Janssens HM, de Jongste JC, and Tiddens HAWM. 2001. Five-fold reduction in lung dose from a static spacer with HFA-Fluticasone: a study in an infant upper airway model. International Paediatric Respiratory and Allergy Congress, Prague.
16. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, and LeSouef PN. 1996. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 51:985-988.
17. Janssens HM, Heijnen EM, de Jong VM, Hop WC, Holland WP, de Jongste JC, and Tiddens HA. 2000. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 16(5):850-856.
18. Kamin WE, Genz T, Roeder S, Scheuch G, Trammer T, Juenemann R, and Cloes RM. 2002. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med 15(1):65-73.
19. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, Borgstrom L, and Le Souef PN. 1997. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 10(9):2023-2028.
20. Bisgaard H, Klug B, Sumby BS, and Burnell PK. 1998. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 11(5):1111-1115.
21. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, and Bisgaard H. 1998. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children [In Process Citation]. Eur Respir J 11 (2):350-354.